Atlanta, GA and Cambridge, MA – (December, 2013) – Inhibikase Therapeutics, Inc. announces the appointment of Marty Joyce, former CFO of Lucid, Inc. and former Executive Vice President and CFO of Biosphere Medical as its Chief Financial Officer.
Marty’s professional background includes leadership roles in public and private, medical device, biotechnology and pharmaceutical companies from start-up stage to over $500 million in annual revenue. He has experience in public equity financings, business development, SEC reporting, strategic planning, mergers, acquisitions, investor relations and biotechnology operations. Since 2012, Marty has served as a consultant to the life science industry assisting biotechnology and pharmaceutical companies in strategic planning, fund raising and operations. From 2011 to 2012, Marty was Chief Financial Officer at Lucid Inc., an early stage skin cancer diagnostic company. Previously, Marty served as Executive Vice President and Chief Financial Officer of BioSphere Medical from January 2006 through 2010. He served as BioSphere’s Chief Financial Officer and Vice President from September 2004 to January 2006. From 2001 to 2004, Marty served as Managing Partner of Stratex Group LLC, a provider of biopharmaceutical executive services to early-stage companies and venture investors. From 1996 to 2001, Marty was North American Chief Financial Officer for Serono Inc. a biotechnology company. Marty received a B.S. in finance from Northeastern University and a M.B.A. from Suffolk University, Boston, Massachusetts.
“The addition of Marty as Chief Financial Officer is the next step in the Company’s transition from a biotech start-up to a full-fledged biopharmaceutical company intending on commercializing its own products to treat infectious disease,” noted Chief Executive Officer Dr. Milton Werner. “Marty’s appointment comes on the heals of the elevation of commercial and product strategic planning at the Board of Directors, which occurred with the appointment in November, 2013 of Anthony Zook, former Global Head of Commercial Operations for Astra Zeneca,”
About Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics is transforming the way pharmaceuticals attack infectious diseases. Its small molecule platform enables treatment of bacterial AND viral infectious disease through a common mechanism of action. The Company’s host-targeting strategy using clinically validated targets treat infectious disease with a low likelihood of stimulating resistance. Founded in 2008 and headquartered in Atlanta, Georgia with offices in Cambridge, Massachusetts, Inhibikase Therapeutics is developing treatments for orphan indications arising from polyomaviruses, such as progressive multifocal leukoencephalopathy (PML), BK-virus associated nephropathy (PVAN), hard-to-treat hepatitis C, fungal and bacterial pneumonias as well as medical countermeasures for biodefense.
# # #